MNMD - MindMed's 2024 Plans: Anxiety Treatment Stands LSD Microdosing For ADHD Will Be Discontinued | Benzinga
Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024.
Clinical Development: Present & Future
MM-120 is Mind Medicine’s lead drug candidate. It’s a tartrate salt form of lysergide (aka LSD) a synthetic tryptamine within the "classic” group of psychedelics that acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors.
MindMed is assessing MM-120 as a potential treatment for Generalized Anxiety Disorder (GAD.) At the advanced clinical stage and having recently provided both statistically significant and clinical topline results (4-week follow-up) in a nearly 200-patient cohort, some of the top features of the results include:
-
100 micrograms achieved the highest level of clinical activity, greatly reducing anxiety in patients by week 4 and eliciting clinical remission in 50% of them.
-
Along with the 200 microgram dose, they elicited a 50%+ improvement in 78% of ...